Dicerna to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium
March 09 2018 - 7:30AM
Business Wire
Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer
of investigational ribonucleic acid interference (RNAi)
therapeutics, today announced that Douglas M. Fambrough, Ph.D.,
president and chief executive officer, will provide a corporate
overview at the B. Riley FBR Inaugural China Healthcare Investing
& Partnering Symposium on Friday, March 16, 2018 at 4:30 p.m.
local time. The conference will be held March 16-17, 2018 at The
InterContinental Hotel Hangzhou.
About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company
focused on the discovery and development of innovative,
subcutaneously delivered RNAi-based therapeutics for diseases
involving the liver, including rare diseases, viral infectious
diseases, chronic liver diseases, and cardiovascular diseases.
Dicerna is leveraging its proprietary GalXC™ RNAi technology
platform to build a broad pipeline in these core therapeutic areas,
focusing on target genes where connections between target gene and
diseases are well understood and documented. Dicerna intends to
discover, develop and commercialize novel therapeutics either on
its own or in collaboration with pharmaceutical partners. For more
information, please visit www.dicerna.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180309005084/en/
Investor:Rx Communications GroupPaula Schwartz,
917-322-2216pschwartz@rxir.comorMedia:SmithSolveAlex Van
Rees, 973-442-1555 ext. 111alex.vanrees@smithsolve.com
Dicerna Pharmaceuticals (NASDAQ:DRNA)
Historical Stock Chart
From Apr 2024 to May 2024
Dicerna Pharmaceuticals (NASDAQ:DRNA)
Historical Stock Chart
From May 2023 to May 2024